Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: Genetic subtype defines antigenic but not neutralization serotype

Journal of Virology

Volumn 85, Issue 9, 2011, Pages 4246-4257

  Tarr, Alexander W ^a   Urbanowicz, Richard A ^a   Hamed, Mohamed R ^a,d   Albecka, Anna ^b,c   McClure, C Patrick ^a   Brown, Richard J P ^a   Irving, William L ^a   Dubuisson, Jean ^b,c   Ball, Jonathan K ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSERM U1019   (France)

^c UNIV LILLE   (France)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOREACTIVITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS ENTRY; VIRUS GENE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTIBODIES, BLOCKING; ANTIBODIES, NEUTRALIZING; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; NEUTRALIZATION TESTS; RNA, VIRAL; SERUM; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 79955384226     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01332-10     Document Type: Article

References (66)

1. Alter, H. J., and L. B. Seeff. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20:17-35.
2. Bartosch, B., et al. 2003. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U. S. A. 100:14199-14204.
3. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
4. Bartosch, B., et al. 2005. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79:8217-8229.
5. Bartosch, B., et al. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630.
6. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
7. Brown, R. J., et al. 2007. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J. Gen. Virol. 88:458-469.
8. Bungyoku, Y., et al. 2009. Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J. Gen. Virol. 90:1681- 1691.
9. Clayton, R. F., et al. 2002. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J. Virol. 76:7672-7682.
10. Cocquerel, L., C. C. Kuo, J. Dubuisson, and S. Levy. 2003. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J. Virol. 77:10677-10683.
11. Cocquerel, L., et al. 2003. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J. Virol. 77:1604-1609.
12. Delgrange, D., et al. 2007. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J. Gen. Virol. 88:2495-2503.
13. Dreux, M., et al. 2006. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281:18285-18295.
14. Drummer, H. E., I. Boo, A. L. Maerz, and P. Poumbourios. 2006. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus gly-coprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 80:7844-7853.
15. Esumi, M., et al. 1999. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 144:973-980.
16. Farci, P., et al. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 93:15394-15399.
17. Flint, M., et al. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
18. Gottwein, J. M., et al. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614-1626.
19. Gottwein, J. M., et al. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
20. Grove, J., et al. 2008. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82:12020- 12029.
21. Hadlock, K. G., et al. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74:10407-10416.
22. Hamed, M. R., et al. 2008. Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease. J. Viral Hepat. 15: 339-345.
23. Johansson, D. X., et al. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 104:16269-16274.
24. Keck, Z. Y., et al. 2004. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78:9224-9232.
25. Lagging, L. M., et al. 2002. Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. J. Infect. Dis. 185:1165-1169.
26. Lavillette, D., et al. 2005. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265-274.
27. Law, M., et al. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14:25-27.
28. Lee, J.-H., W. K. Roth, and S. Zeuzem. 1997. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J. Hepatol. 26:1001-1009.
29. Lindenbach, B. D., et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
30. Logvinoff, C., et al. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:10149-10154.
31. Majid, A., et al. 1999. Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. J. Gen. Virol. 80:317-325.
32. Mascola, J. R., et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340-348.
33. McKeating, J. A., et al. 2004. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 78:8496-8505.
34. Meunier, J. C., et al. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipo-protein C1. Proc. Natl. Acad. Sci. U. S. A. 102:4560-4565.
35. Meunier, J. C, et al. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82:966-973.
36. Meyer, K., M. Ait-Goughoulte, Z. Y. Keck, S. Foung, and R. Ray. 2008. Antibody-dependent enhancement of hepatitis C virus infection. J. Virol. 82:2140-2149.
37. Mohsen, A. H. 2001. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 48:707-713.
38. Montefiori, D. C, et al. 1998. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72:3427-3431.
39. Moore, J. P., et al. 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
40. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
41. Op De Beeck, A. O., et al. 2004. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78:2994-3002.
42. Owsianka, A., R. F. Clayton, L. D. Loomis-Price, J. A. McKeating, and A. H. Patel. 2001. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82:1877-1883.
43. Owsianka, A., et al. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79:11095-11104.
44. Owsianka, A. M., et al. 2008. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89:653-659.
45. Owsianka, A. M., et al. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80:8695-8704.
46. Perotti, M., et al. 2007. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the Hcv\E2 protein. J. Virol. 82:1047-1052.
47. Pestka, J. M., et al. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 104:6025-6030.
48. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 24:493-497.
49. Scarselli, E., et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
50. Schilling, R., et al. 2003. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J. Virol. 77:8882-8892.
51. Schutten, M., A. C. Andeweg, G. F. Rimmelzwaan, and A. D. Osterhaus. 1997. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies. J. Gen. Virol. 78:999- 1006.
52. Shang, D., W. Zhai, and J. P. Allain. 1999. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Virology 258:396-405.
53. Simmonds, P., et al. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
54. Simmonds, P., et al. 1993. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74:2391-2399.
55. Simmonds, P., et al. 1994. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J. Gen. Virol. 75:1053-1061.
56. Tarr, A. W., et al. 2007. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J. Gen. Virol. 88:2991-3001.
57. Tarr, A. W., A. M. Owsianka, A. Szwejk, J. K. Ball, and A. H. Patel. 2007. Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol. Biol. 379:177-197.
58. Tarr, A. W., et al. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601.
59. Voisset, C., et al. 2005. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280:7793-7799.
60. Voisset, C., et al. 2006. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J. Gen. Virol. 87:2577-2581.
61. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
62. Yi, M., Y. Ma, J. Yates, and S. M. Lemon. 2007. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81:629-638.
63. Youn, J. W., et al. 2005. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42:1429-1436.
64. Zeuzem, S. 2001. The kinetics of hepatitis C virus infection. Clin. Liver Dis. 5:917-930.
65. Zhong, J., et al. 2006. Persistent hepatitis C virus infection in vitro: coevo-lution of virus and host. J. Virol. 80:11082-11093.
66. Zibert, A., W. Kraas, H. Meisel, G. Jung, and M. Roggendorf. 1997. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J. Virol. 71:4123-4127.